WebFeb 14, 2024 · Overall, 152 patients with histologically confirmed pRCC and up to one prior line of therapy, excluding sunitinib, were randomly assigned to receive one of four regimens: cabozantinib 60 mg/day; sunitinib 50 mg/day on a 4-week on, 2-week off schedule; crizotinib 250 mg twice daily; orsavolitinib 600 mg/day. WebThis is where clinical trials are tailored to an individual subtype of disease, for example, the SWOG S1500 PAPMET trial that randomized patients with type I papillary RCC to either …
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a ...
WebFeb 13, 2024 · SWOG S1500 (NCT02761057), also called PAPMET, was a randomized phase 2 trial comparing cabozantinib, crizotinib and savolitinib to sunitinib, a VEGF … WebFeb 14, 2024 · The Phase II PAPMET study (NCT02761057) demonstrated that cabozantinib resulted in a significant improvement in progression-free survival in metastatic papillary renal cell carcinoma (pRCC), compared to sunitinib. Dr. slack max attachment size
Kidney cancer at ASCO GU: PAPMET & CLEAR VJOncology
WebJun 1, 2024 · The PAPMET trial was a pivotal study that changed the standard of care for non-clear cell kidney cancer. It’s one of the few randomized clinical trials available that has demonstrated... WebFeb 28, 2024 · Its regulatory approval in renal cell carcinoma was based on the results of two prospective clinical trials limited to a population with clear-cell renal cell carcinoma. , Only two small retrospective studies , have reported on the effects of cabozantinib in non-clear-cell renal cell carcinoma, and both showed encouraging activity. WebDownload scientific diagram Schema for the SWOG clinical trial-PAPMET showing randomization of patients with metastatic papillary RCC to 4 arms (sunitinib, cabozantinib, crizotinib, savolitinib). slack mop company